| Presentation | Media | Date |
Intervjun hos Redeye med vd Martin Jönsson
| |
|
6 maj, 2024
|
SITDOWN hos Finwire - AlzeCures vd, Martin Jönsson om emissionen
| |
|
2 maj, 2024
|
Intervjun hos Finwire med Johan Sandin, CSO
| |
|
2 maj, 2024
|
Emissions presentation hos Redeye med vd Martin Jönsson
| |
|
2 maj, 2024
|
AlzeCures VD Martin Jönsson hos Redeye
| |
|
11 april, 2024
|
Vd Martin Jönsson presenterar hos Finwire
| |
|
10 april, 2024
|
AlzeCures VD Martin Jönsson på Redeye's event om Alzheimer
| |
|
21 mars, 2024
|
AlzeCure presenterar nya prekliniska data med NeuroRestore ACD856 på ledande Alzheimer-konferens, AD/PD 2024 (engelska)
|
|
|
7 mars, 2024
|
Vd Martin Jönssons på Sitdown med Finwire
| |
|
28 februari, 2024
|
Vd Martin Jönsson hos Redeye
| |
|
27 februari, 2024
|
Expert Event - Advances in the treatment of Alzheimer’s disease – Small molecule Gamma-Secretase Modulators (GSMs) as promising disease-modifying treatments together
|
|
|
19 februari, 2024
|
Alzstatin: a small molecule disease modifying and preventive therapy against Alzheimer’s – Johan Sandin, PhD, CSO, AlzeCure; AlzeCure Pharma expert event with Johan Sandin, PhD, CSO, AlzeCure
|
|
|
19 februari, 2024
|
Alzheimer’s disease and the amyloid hypothesis – Professor Henrik Zetterberg, MD, PhD, Gothenburg University & University College London, AlzeCure Pharma expert event
|
|
|
19 februari, 2024
|
Welcome address, agenda & company overview, – Martin Jönsson, CEO, AlzeCure; AlzeCure Pharma expert event - Alzheimer’s around highly current gamma-secretase modulators
|
|
|
19 februari, 2024
|